← All trials
NCT03657784
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 13, 2017
- Primary completion
- Dec 31, 2018
- Completion date
- Jun 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- GuerbetLead sponsor
- Carol Davila University of Medicine and PharmacyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.